secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001213900-24-043229
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma licenses BLEX 404 for TNBC to OncoX in deal worth up to $13.75M plus royalties
--------------------------------------------------------------------------------

- Definitive license agreement with OncoX BioPharma for exclusive rights to develop and commercialize BLEX 404 for TNBC in 50% of worldwide markets for 20 years.
- Total license fee of $6.25M (or 1.25M OncoX shares at $5/share) due 30 days after signing; additional milestone of $625k cash after OncoX's next fundraising (no guarantee).
- ABVC and its subsidiary BioLite each signed identical agreements; aggregate potential payments including royalties up to $13.75M (press release states $12.5M license fee and $1.25M milestone).
- Royalties of 5% of net sales on licensed product, up to $12.5M, starting from first commercial sale (uncertain).
- US FDA has approved four INDs for ABVC's BLEX 404 combination therapy, including for TNBC (IND 129575).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024043229/0001213900-24-043229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024043229/ea0206070-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-043229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer